Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%.
Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a...
From other sites
Video at CNBC.com (Fri, 1:54PM)
Video at CNBC.com (Wed, 5:40PM)
Video at CNBC.com (Mon, 12:06PM)
Video at CNBC.com (Mon, 12:00PM)
Video at CNBC.com (Jul 21, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs